Cargando…

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial

BACKGROUND: Hospitalized patients are at increased risk for candidemia and invasive candidiasis (C/IC). Improved therapeutic regimens with enhanced clinical and pharmacoeconomic outcomes utilizing existing antifungal agents are still needed. METHODS: An open-label, non-comparative study evaluated an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vazquez, Jose, Reboli, Annette C, Pappas, Peter G, Patterson, Thomas F, Reinhardt, John, Chin-Hong, Peter, Tobin, Ellis, Kett, Daniel H, Biswas, Pinaki, Swanson, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944438/ https://www.ncbi.nlm.nih.gov/pubmed/24559321 http://dx.doi.org/10.1186/1471-2334-14-97

Ejemplares similares

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
por: Reboli, Annette C, et al.
Publicado: (2011)

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
por: Ruhnke, M, et al.
Publicado: (2011)

Anidulafungin compared with fluconazole therapy in critically ill patients
por: Kett, DH, et al.
Publicado: (2010)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil
por: Vianna, Cid Manso de Mello, et al.
Publicado: (2023)

Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020)

375. Tolerability of Anidulafungin for Candidemia in Patients With Hepatic or Renal Dysfunction
por: Kim, Ji Young, et al.
Publicado: (2018)

Safety and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children
por: Roilides, Emmanuel, et al.
Publicado: (2017)

In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates
por: Buil, J B, et al.
Publicado: (2020)

Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis
por: Xie, Rujia, et al.
Publicado: (2020)

817. Caspofungin versus Anidulafungin in Patients with Candidemia: Retrospective Comparative Study
por: Elajez, Reem, et al.
Publicado: (2023)

Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial
por: Mootsikapun, Piroon, et al.
Publicado: (2013)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
por: Ruhnke, M, et al.
Publicado: (2012)

1173. Ocular Candidiasis in Patients with Candidemia Diagnosed by Blood Culture Versus T2Candida® Assay
por: White, Cameron, et al.
Publicado: (2020)

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
por: Auzinger, Georg, et al.
Publicado: (2015)

2116. Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis
por: Demir, Koray K, et al.
Publicado: (2019)

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials
por: Kullberg, Bart Jan, et al.
Publicado: (2017)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

2111. Anidulafungin vs. Micafungin Treatment in Adult Patients with Candidemia: A Retrospective Study of Single-Center Experience
por: Suh, Jinwoong, et al.
Publicado: (2019)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

Propranolol Ameliorates the Antifungal Activity of Azoles in Invasive Candidiasis
por: Mayandi, Venkatesh, et al.
Publicado: (2023)

Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies
por: Sganga, Gabriele, et al.
Publicado: (2019)

P079 Virulence factors and azole-resistant mechanism of Candida tropicalis isolated from candidemia
por: Sarvestani, Elahe Sasani, et al.
Publicado: (2022)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel
por: Clancy, Cornelius J, et al.
Publicado: (2017)

Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study
por: Hasan, Md Jahidul, et al.
Publicado: (2022)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

Ocular Candidiasis in Patients with Candidemia at a Large Tertiary Care Center
por: Lee, Bonny, et al.
Publicado: (2017)

Incidence of candidemia and prevalence of azole-resistant candidemia at a tertiary South African hospital – A retrospective laboratory analysis 2016–2020
por: Chibabhai, Vindana
Publicado: (2022)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

β-D-glucan Surveillance with Preemptive Anidulafungin for Invasive Candidiasis in Intensive Care Unit Patients: A Randomized Pilot Study
por: Hanson, Kimberly E., et al.
Publicado: (2012)

Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies
por: De Rosa, Francesco Giuseppe, et al.
Publicado: (2021)

Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines
por: Vasileiou, Eleni, et al.
Publicado: (2018)

Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia
por: Sakai, Daiki, et al.
Publicado: (2021)

1702. Disseminated Candidiasis after Candidemia: Epidemiology, Diagnostic Evaluation, and Risk Factors
por: Whitehurst, Daniel, et al.
Publicado: (2023)

1697. Comparison of Candidemia in Patients in Neonatal Intensive Care Unit and Pediatric Patients and Big Data Analysis on Candidiasis and Candidemia in Korean Children
por: Choi, Joon-sik, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nhvp0nd79b3n1u548t94ccpdi1